Fragmento

Dear Editor: Telaprevir combination with pegylated-interferon (Peg-IFN) +ribavirin significantly improves response rates in HCV infection. However this triple regimen is particularly associated with increased rates of side effects. HCV infection in patients undergoing hematopoietic stem cell transplantation (HSCT) increases the risks of liver-related complications and veno-occlusive disorder. Cure of HCV before transplantation can eliminate these risks. We present a patient with severe aplastic anemia and chronic hepatitis C treated with telaprevir based triple regimen before HSCT. A 24-year-old male had been diagnosed as severe aplastic anemia and chronic HCV infection. Initial tests revealed the followings: leukocytes 2500/mm³, neutophils 570/mm³, Hb 11.5 mg/mL, platelets 42,000/mm³. HCV RNA level was 1,350,000 IU/mL and genotype 1b. Liver biopsy revealed moderate inflammation, mild fibrosis and iron deposition due to multiple transfusions. A detailed informed consent was obtained and he was given modified doses of Peg-IFN-á2a (135 mcg/week) + ribavirin (600 mg/day) and full dose telaprevir (2,250 mg/day).

Palabras clave:

2014-10-30   |   374 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.6. Noviembre-Diciembre 2014 Pags. 843-844 Ann Hepatol 2014; 13(6)